LASERMASTER TECHNOLOGIES, INC. ANNOUNCES OEM AGREEMENT WITH MICROGRAFX, INC.
LASERMASTER TECHNOLOGIES, INC. ANNOUNCES OEM AGREEMENT WITH MICROGRAFX, INC. MINNEAPOLIS, Nov. 20 /PRNewswire/ -- LaserMaster Technologies, Inc. (NASDAQ: LMTS) today announced an agreement between Digital Typeface Corporation (DTC), one of its subsidiaries, and Micrografx, Inc. The agreement will allow Micrografx to include 167 DTC Type 1 typefaces with Micrografx Designer(TM), a $695 illustration program that works with Microsoft(R) Windows(TM). All typefaces can be used with other Windows applications. Sold separately, these DTC typefaces have a value of over $1,500. This relationship marks LaserMaster's entry into OEM markets for its proprietary technology and digital typeface outlines. "We selected DTC as our typeface supplier because of the high quality and variety of typefaces available in their Master Works Typeface Library," said Lyle Griffin, Micrografx's vice president of development. "By including such a large number of high-quality, Type 1 typefaces with our application, we are enhancing our leadership position in desktop illustration software." "With this agreement, DTC and Micrografx have developed a dynamic typeface solution for desktop illustrators," said Lee Newstrom, DTC's vice president of OEM sales. "By bundling so many typefaces with the Designer application -- without sacrificing quality -- DTC and Micrografx have raised the industry's typeface standards for desktop illustration software." LaserMaster Technologies, Inc. designs, manufactures and markets high resolution, high performance printing systems for the microcomputer market. The LaserMaster product line features the company's proprietary TurboRes(R) resolution enhancement technology -0- 11/20/91 /CONTACT: Karen Neset of LaserMaster Technologies, 612-941-8687/ (LMTS) CO: LaserMaster Technologies ST: Minnesota IN: CPR SU:
KH -- MN002 -- 5287 11/20/91 09:26 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 20, 1991|
|Previous Article:||ENHANCED SURVIVAL FOR MELANOMA PATIENTS ON RIBI THERAPY SUGGESTED BY NEW TEST FOR IMMUNOLOGICAL RESPONSE|
|Next Article:||RAC MORTGAGE INVESTMENT CORPORATION ANNOUNCES NOVEMBER DIVIDEND|